PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.

Slides:



Advertisements
Similar presentations
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
Advertisements

JNC 8 Guidelines….
National Institute for Health and Clinical Excellence.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Hypertension Guidelines 2014
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Blood Pressure Monitoring
Hypertension: what is new…and old GREG FOTIEO, MD.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.
Hypertension: JNC 7 Guidelines Steven W Harris MHS PA-C.
Pharmacological Treatment of Hypertension Update 2012.
Drugs for Hypertension
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Selection of Antihypertensive Drug
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
HOME AND AMBULATORY BLOOD PRESSURE MONITORING
Systemic Hypertension. Systemic blood pressure measures 140/90 mm Hg or higher on at least two occasions a minimum of 1 to 2 weeks apart.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
DR. IDOWU AKOLADE EDM DIVISION LUTH
1 1 Individualized Therapy forHypertension Introduction to Primary Care: a course of the Center of Post Graduate Studies in FM PO Box – Riyadh
Daily Dilemmas in Hypertension Management. Objectives Review the impact of hypertension on society Review the impact of hypertension on society Review.
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
 Update on Hypertension Troy L. Randle, DO, FACC, FACOI.
Hypertension Guidelines 2015 Barry D. Bertolet, MD Cardiology Associates of North Mississippi Tupelo – Columbus – Starkville - Oxford.
Report from the panel members appointed to the Eighth Joint National Committee (JNC 8) 2014 evidence-based guidelines for the management of high blood.
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
1 Current & New treatment strategies to address CV Risk.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Hypertension Mohammad Garakyaraghi,MD Cardiologist Associate Professor.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
CCB in Management of Hypertension in Older Persons Presented by Mona Ahmed sherif Marwa Shaaban Shimaa Adel Ahmed Salma Sadek Alia khalid.
2007 Hypertension as a Public Health Risk January, 2007.
Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
Therapeutics Conference. Fluid Resuscitation Early correction of fluid deficit is essential in hypovolemic shock to prevent decline in tissue perfusion.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
HTN & CKD 1. HTN has been reported to occur in 85-95% of patients with CKD (stages 3–5). The relationship between HTN & CKD is cyclic in nature. Uncontrolled.
April 22, 2016 Connie Tien Daniel Kim Jeffrey Hughes Michelle Di Fiore
Managing Blood Pressure in the Older Adult Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
Management of Hypertension according to JNC 7
Hypertension In The Stroke Patient
Nephrology Journal Club The SPRINT Trial Parker Gregg
David Antecol, M.D., FACC, FASH, FRCP(C) Specialist in Clinical Hypertension (American Society of Hypertension) Disclosures: None.
Hypertension guidelines What’s all the controversy about 2015
JNC VIII Hypertension.
Hypertension JNC VIII Guidelines.
Hypertension Guidelines-JNC 8
Drugs for Hypertension
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Achieving the Clinical Potential of RAAS Blockade
Systolic Blood Pressure Intervention Trial (SPRINT)
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Step Care Therapy for Hypertension in Diabetic Patients
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Primary Hypertension Max C. Reif, M.D.
Pharmacological Treatment of Hypertension Update 2012
JNC Evidence-Based Guideline for the Management of
Presentation transcript:

PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015

Prevalence of Hypertension Adults have elevated Blood Pressure Patients with HTN Diagnosed HTN 78% Treated HTN 68% Uncontrolled HTN 38% Resistant HTN 9% Patients with HTN Diagnosed HTN Treated HTN Uncontrolled HTN HTN=Hypertension

Only relying on manual office pressures misses out on white coat and masked hypertension Manual Office BP mmHg Ambulatory BP mmHg Hypertension Normotension White Coat Hypertension Masked Hypertension

The prognosis of masked hypertension Prevalence is approximately 10% in hypertensive patients Normal 23/685 White coat 24/656 Uncontrolled 41/462 Masked 236/3125 CV events per 1000 patient-year CV Events Okhubo et al. J. Am. Coll. Cardiol. 2012;46;

What’s The Worst That Could Happen?

Importance OF HTN HTN is the most important modifiable CV risk factor HTN is the commonest cause of premature death HTN is the commonest cause of CKD & commonest cause of ESRD in elderly Continuum of increasing CV risk from SBP 115mmHg CV mortality doubles for every10/5 increase in BP>120/70 High BP causes: 35% of all cardiovascular deaths 50% of all stroke deaths 25% of all CAD deaths 50% of all congestive heart failure

Benefits of Lowering BP

New Guidelines for Hypertension National Institute for Health and Clinical Excellence (NICE), 2011 Kidney Disease: Improving Global Outcome (KDIGO), 2012 European Society of Hypertension/European Society of Cardiology, (ESH/ESC), 2013 American Diabetes Association (ADA), 2014 American Society of Hypertension and the International Society of Hypertension (ASH/ISH), 2014 Eighth Joint National Committee (JNC8), 2014

JNC Evidence-Based Guideline for the Management of High Blood Pressure in Adults

JNC 8 (2014 Hypertension Guideline Management Algorithm) 1

2

PopulationGoal BP, mm Hg Initial Drug Treatment Options General ≥60 y<150/90Nonblack: thiazide-type diuretic, ACEI, ARB, or CCB Black: thiazide-type diuretic or CCB General <60 y<140/90Nonblack: thiazide-type diuretic, ACEI, ARB, or CCB Black: thiazide-type diuretic or CCB Diabetes<140/90Thiazide-type diuretic, ACEI, ARB, or CCB CKD<140/90ACEI or ARB

Start one drug, titrate to maximum dose, and then add a second drug Start one drug and then add a second drug before achieving maximum dose of the initial drug Begin with 2 drugs at the same time, either as 2 separate pills or as a single pill combination Strategies to Dose of Antihypertensive Drugs

Ratio of Incremental SBP lowering effect at “standard dose”– Combine or Double? Incremenal SBP reduction ratioObserved/Expected (additive)

BP lowering effects from antihypertensive drugs  Dose response curves for efficacy are relatively flat  80% of the BP lowering efficacy is achieved at half-standard dose  Combinations of standard doses have additive blood pressure lowering effects

key issues must be addressed during the initial office evaluation of a person with elevated BP readings:  Documenting that the BP is elevated  Defining the presence or absence of TOD related to hypertension 3. Screening for other CV risk factors that often accompany hypertension 4. Estimating the person’s absolute risk for CV and renal disease 5. Assessing whether the person is likely to have an identifiable cause of HTN (secondary HTN) and should have further diagnostic testing to confirm or exclude that diagnosis 6. Obtaining data that may be helpful in the initial and subsequent choices for therapy.

GENERAL RULES 1-Decrease CV mortality :ACEI ;ARBs, Diuretics, 2-Age:Elderly,Middle age,Women at reproductive age 3- Race/Ethnicity : Blacks,African-American,whites,…. 4- Concomitant disease & Conditions: BPH,CRF,Asthma, … 5- Compelling indications:Post MI,CKD, stroke,DM,CHF, CAD,… 6-Long acting Drugs : Patient compliance 7-Start low (dosage)&go slow

Treatment of Hypertension CONSIDER Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect Dual Combination Triple Therapy Lifestyle modification Thiazide diuretic ACEI Long-acting CCB TARGET <140/90 mmHg For age<60 & <150/90 mmHg For age ≥60 ARB Initial therapy A combination of 2 first line drugs may be considered as initial therapy if the blood pressure is >20 mmHg systolic or > 10 mmHg diastolic above target

Treatment of Isolated Systolic Hypertension CONSIDER Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect Thiazide Amlodipin Dual therapy Triple therapy Lifestyle modification therapy ARB or ACEI TARGET : SBP 60 years *If blood pressure is still not controlled, or there are adverse effects, other classes of antihypertensive drugs may be combined

Choice of Pharmacological Treatment for Hypertension Compelling indications: Stable IHD Recent ST Elevation-MI or non-ST Elevation-MI LV Systolic Dysfunction Cerebrovascular Disease Non Diabetic CKD Diabetes Mellitus With Nephropathy Without Nephropathy

Treatment of HTN in Patients with Stable IHD Caution should be exercised when combining (Verapamil Or Diltiazem) +beta-blocker If abnormal systolic left ventricular function: avoid (Verapamil or Diltiazem) Dual therapy with an ACEI +ARB are not recommended in the absence of refractory CHF The combination of an ACEi and CCB is preferred 1. Beta-blocker 2. Long-acting CCB Stable angina ACEI are recommended for most patients with established CAD* ARBs are not inferior to ACEI in IHD Short-acting nifedipine

Treatment of HTN in Patients with Recent STEMI or NSTEMI Amlodipine* (Avoid diltiazem, verapamil) Beta-blocker +ACEI (or ARB) Recent myocardial infarction CHF? NO YES Long-acting CCB If beta-blocker contraindicated( Asthma, COPD, Heart Block,….) or not effective *

Treatment of HTN with LV Systolic Dysfunction If additional therapy is needed: Diuretic (Thiazide for hypertension; Loop for volume control Or eGFR,30cc/min) Spironolactone : for CHF NYHA-FC II-IV or post MI (clinical HF Or LVEF<40% Or DM) Systolic LV dysfunction ACEI(or ARB)+Beta blocker (carvedilol Or metoprolol) Up titrate doses of ACEI or ARB If ACEI and ARB are contraindicated: Hydralazine + Isosorbide dinitrate If additional antihypertensive therapy is needed: ACEI / ARB Combination Amlodipine Verapamil Diltiazem

Treatment of HTN in Association With Stroke Acute Stroke: Onset to 72 Hours Treat extreme BP elevation (systolic > 220 mmHg, diastolic > 120 mmHg) by 15-25% over the first 24 hour with gradual reduction after. Acute ischemic Stroke Avoid excessive lowering of BP which can exacerbate ischemia

Strongly consider blood pressure reduction in all patients after the acute phase of stroke or TIA. Target BP < 140/90 mmHg An ACEI / diuretic combination is preferred Stroke TIA Combinations of an ACEI with an ARB are not recommended Treatment of HTN in Association With Stroke Acute Stroke: After72 Hours

Treatment of HTN in Patients with Non Diabetic CKD Chronic kidney disease and proteinuria * ACEI(or ARB)±Diuretic(Thiazide Or Loop) Combination with other agents Target BP: < 140/90 mmHg * albumin:creatinine ratio [ACR] > 30 mg/mmol or urinary protein > 500 mg/24hr Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB Combinations of a ACEI and a ARB are specifically not recommended in the absence of proteinuria

Treatment of Hypertension in association with Diabetes Mellitus

Treatment of HTN in DM without CKD Threshold ≥130/80 mmHg and Target below 130/80 mmHg * Combinations of an ACEI with an ARB are specifically not recommended

If eGFR <30 ml/min, a Furosemide should be substituted for a thiazide THRESHOLD equal or over 130/80 mmHg and TARGET below 130/80 mmHg DIABETES with Nephropathy ACE Inhibitor or ARB IF ACEI and ARB are contraindicated or not tolerated, SUBSTITUTE: Long-acting CCB Thiazide Addition of one or more of Long-acting CCB or Thiazide drugs combination may be needed Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB Treatment of HTN in DM +CKD

The use of the combination of ACE inhibitor with an ARB should only be considered in selected and closely monitored Patients with Refractory CHF or Marked proteinuria.